Estrella Immunopharma appoints Hong Zhang as Chairperson and Board member

Estrella Immunopharma, Inc.

Hong Zhang appointed Chairperson and director effective Aug 14, 2024; board expands from 5 to 6.
Ms. Zhang brings 25+ years financial and corporate strategy experience; previous Chairman Dr. Cheng Liu remains on board.
Compensation: $5,000/quarter as director + $2,500/quarter as Chairperson; expenses reimbursed.
Company also negotiating consulting agreement with entity owned by Ms. Zhang for Asian strategic initiatives; terms pending approval.
Press release notes dosing of first patient in Phase I/II trial STARLIGHT-1 for EB103 in R/R B-cell NHL.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Hong Zhang

Chairperson and a member of the Board of Directors

ESLA · Estrella Immunopharma, Inc.

Effective: 2024-08-14
Filed: August 20, 2024, 7:59 PM ET

On August 14, 2024, the Board of Directors of Estrella Immunopharma, Inc. (the “Company”) appointed Ms. Hong Zhang as Chairperson and a member of the Company’s Board of Directors (the “Board”), effective as of the same date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Hong Zhang was appointed as Chairperson and a member of the Board of Directors at Estrella Immunopharma, Inc..

Action: appointed
Role: Chairperson and a member of the Board of Directors

Exact text from the filing

On August 14, 2024, the Board of Directors of Estrella Immunopharma, Inc. (the “Company”) appointed Ms. Hong Zhang as Chairperson and a member of the Company’s Board of Directors (the “Board”), effective as of the same date.

View on SEC.gov

Estrella Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-071174

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.